Patient Square Capital, a health care investment firm, completed the acquisition of a majority stake in Apollo Therapeutics, a biopharmaceutical company, for $145m. Other investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund participated in the acquisition. "Patient Square continues to be very enthusiastic about that business model. We are extremely excited to partner with the team at Apollo, as we see tremendous potential in their product portfolio and their novel partnership approach with three of the world’s top academic institutions pursuing some of the most innovative science globally. We look forward to working closely with the Apollo team to broaden their reach globally and to bring a number of potentially life-changing medicines to patients," Jim Momtazee, Patient Square Managing Partner.